The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $372.71

Today's change-2.85 -0.76%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $372.71

Today's change-2.85 -0.76%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$2.85

Regeneron Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$2.85 or 0.76% to (U.S.)$372.71. Over the last five days, shares have lost 6.39% and are down 31.34% for the last year to date. This security has underperformed the S&P 500 by 37.25% during the last year.

Key company metrics

  • Open(U.S.) $375.85
  • Previous close(U.S.) $375.56
  • High(U.S.) $378.50
  • Low(U.S.) $371.32
  • Bid / Ask(U.S.) $336.33 / (U.S.) $393.50
  • YTD % change-31.34%
  • Volume723,571
  • Average volume (10-day)908,977
  • Average volume (1-month)1,002,858
  • Average volume (3-month)831,007
  • 52-week range(U.S.) $325.35 to (U.S.) $563.79
  • Beta1.83
  • Trailing P/E54.29×
  • P/E 1 year forward31.78×
  • Forward PEG1.67×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.87
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.17%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue1,2201,2131,2011,098
Total other revenue--------
Total revenue1,2201,2131,2011,098
Gross profit1,1761,1441,089987
Total cost of revenue4469112111
Total operating expense857921872869
Selling / general / administrative270292290295
Research & development543560470461
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------2
Other operating expenses, total--------
Operating income363292329229
Interest income (expense), net non-operating-------4
Gain (loss) on sale of assets--------
Other--------
Income before tax366292330227
Income after tax265196181155
Income tax, total1019614972
Net income265196181155
Total adjustments to net income--------
Net income before extra. items265196181155
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items265196181155
Inc. avail. to common incl. extra. items265196181155
Diluted net income265196182155
Dilution adjustment0000
Diluted weighted average shares116116116115
Diluted EPS excluding extraordinary itemsvalue per share2.271.691.561.34
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share2.271.691.561.35